An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples In a recent study by US researchers (currently available on the medRxiv* preprint server), a specific immunoassay based on the spike glycoprotein’s receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only well suited for the detection of antibody response after infection and vaccination but may also represent a method of choice when conducting seroepidemiological studies. Following the burden and spread of SARS-CoV-2 infection during the coronavirus disease (COVID-19) pandemic is of utmost importance in small environments, but also larger geographical settings. Basically, all of our current data is derived following the use of two different classes of assays.